Neurizon Therapeutics Limited (ASX:NUZ)

Market Cap	46.27M -35.2%
Revenue (ttm)	5.98M +294.5%
Net Income	-14.85M
EPS	-0.03
Shares Out	746.27M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,540,941
Open	0.0630
Previous Close	0.0630
Day's Range	0.0620 - 0.0690
52-Week Range	0.0610 - 0.1850
Beta	1.33
Analysts	n/a
Price Target	n/a
Earnings Date	May 5, 2026

About Neurizon Therapeutics

Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases. Its lead candidate is NUZ-001, a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024. Neur...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 4
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: NUZ

Financial Performance

In fiscal year 2025, Neurizon Therapeutics's revenue was 1.54 million, an increase of 82.70% compared to the previous year's 841,713. Losses were -16.59 million, 116.3% more than in 2024.